Poly (ADP-ribose) Polymerase (PARP) has a well-established function in DNA restore processes, and small molecule inhibitors of PARP have been developed as chemotherapy sensitisers for the therapy of most cancers. The following demonstration that PARP inhibition is selective for BRCA1 or BRCA2 deficiency means that PARP inhibitors could also be notably helpful for the therapy of most cancers with BRCA mutations. This could characterize one of many first clinically carried out examples of an artificial deadly method for most cancers therapy.
Nonetheless, there are nonetheless unanswered questions surrounding PARP inhibitors, particularly the degrees of specificity and efficiency which are required to elicit BRCA selectivity. The latest identification of mechanisms of mobile resistance to PARP inhibitors might present indications as to how these medicine could also be greatest used within the clinic. The Ataxia Telangiectasia Mutated (ATM) gene is steadily inactivated in lymphoid malignancies corresponding to persistent lymphocytic leukemia (CLL),
T-prolymphocytic leukemia (T-PLL), and mantle cell lymphoma (MCL) and is related to faulty apoptosis in response to alkylating brokers and purine analogues. ATM mutant cells exhibit impaired DNA double strand break restore. Poly (ADP-ribose) polymerase (PARP) inhibition that imposes the requirement for DNA double strand break restore ought to selectively sensitize ATM-deficient tumor cells to killing. We investigated in vitro sensitivity to the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) of 5 ATM mutant lymphoblastoid cell strains (LCL), an ATM mutant MCL cell line,
an ATM knockdown PGA CLL cell line, and 9 ATM-deficient major CLLs induced to cycle and noticed differential killing in contrast with ATM wildtype counterparts. Pharmacologic inhibition of ATM and ATM knockdown confirmed the impact was ATM-dependent and mediated by way of mitotic disaster independently of apoptosis. A nonobese diabetic/extreme mixed immunodeficient (NOD/SCID) murine xenograft mannequin of an ATM mutant MCL cell line demonstrated considerably decreased tumor load and an elevated survival of animals after olaparib therapy in vivo. Addition of olaparib sensitized ATM null tumor cells to DNA-damaging brokers. We propose that olaparib can be an applicable agent for treating refractory ATM mutant lymphoid tumors.
Part I examine of PARP inhibitor ABT-888 together with topotecan in adults with refractory strong tumors and lymphomas.
A part I trial of ABT-888 (veliparib), a PARP inhibitor, together with topotecan, a topoisomerase I-targeted agent, was carried out to find out most tolerated dose (MTD), security, pharmacokinetics, and pharmacodynamics of the mixture in sufferers with refractory strong tumors and lymphomas. Various schedules and doses of intravenous topotecan together with ABT-888 (10 mg) administered orally twice a day (BID) have been evaluated. Plasma and urine pharmacokinetics have been assessed and ranges of poly(ADP-ribose) (PAR) and the DNA injury marker γH2AX have been measured in tumor and peripheral blood mononuclear cells (PBMC).
Twenty-four sufferers have been enrolled. Vital myelosuppression restricted the power to coadminister ABT-888 with commonplace doses of topotecan, necessitating dose reductions. Preclinical research utilizing athymic mice carrying human tumor xenografts additionally knowledgeable schedule adjustments. The MTD was established as topotecan 0.6 mg/m²/d and ABT-888 10 mg BID on days one to 5 of 21-day cycles. Topotecan didn’t alter the pharmacokinetics of ABT-888.
A greater than 75% discount in PAR ranges was noticed in three paired tumor biopsy samples; a better than 50% discount was noticed in PBMCs from 19 of 23 sufferers with measurable ranges. Will increase in γH2AX response in circulating tumor cells (CTC) and PBMCs have been noticed in sufferers receiving ABT-888 with topotecan. We present a mechanistic interplay of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, and CTCs. Outcomes of this trial reveal that PARP inhibition can modulate the capability to restore topoisomerase I-mediated DNA injury within the clinic
Twin roles of PARP-1 promote most cancers progress and development.
PARP-1 is an ample nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation. PARP-1 has well-described capabilities in DNA injury restore and in addition capabilities as a context-specific regulator of transcription elements. With a number of fashions, knowledge present that PARP-1 elicits protumorigenic results in androgen receptor (AR)-positive prostate most cancers cells, in each the presence and absence of genotoxic insult. Mechanistically, PARP-1 is recruited to websites of AR perform, therein selling AR occupancy and AR perform.
It was additional confirmed in genetically outlined programs that PARP-1 helps AR transcriptional perform, and that in fashions of superior prostate most cancers, PARP-1 enzymatic exercise is enhanced, additional linking PARP-1 to AR exercise and illness development. In vivo analyses present that PARP-1 exercise is required for AR perform in xenograft tumors, in addition to tumor cell progress in vivo and technology and upkeep of castration resistance. Collectively, these research establish novel capabilities of PARP-1 in selling illness development, and in the end counsel that the twin capabilities of PARP-1 could be focused in human prostate most cancers to suppress tumor progress and development to castration resistance.
 Antibody) Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx145140-96tests |
Abbexa |
96 tests |
EUR 337.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx238257-100g |
Abbexa |
100 µg |
EUR 350 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx238257-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx302290-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
20-abx302290 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx302290-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx302290-50g |
Abbexa |
50 µg |
EUR 250 |
 Antibody) Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx027593-400l |
Abbexa |
400 µl |
EUR 518.75 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx027593-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx027593-80l |
Abbexa |
80 µl |
EUR 250 |
|
|
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx375499-96tests |
Abbexa |
96 tests |
EUR 337.5 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx376324-96tests |
Abbexa |
96 tests |
EUR 225 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx344921-100l |
Abbexa |
100 µl |
EUR 250 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx344921-50l |
Abbexa |
50 µl |
EUR 187.5 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
20-abx149592 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
 Antibody) Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx027441-400l |
Abbexa |
400 µl |
EUR 518.75 |
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx027441-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx027441-80l |
Abbexa |
80 µl |
EUR 281.25 |
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx111352-100l |
Abbexa |
100 µl |
EUR 612.5 |
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
20-abx111352 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx331930-100ul |
Abbexa |
100 ul |
EUR 510 |
|
|
 Antibody) Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx135754-100tests |
Abbexa |
100 tests |
EUR 175 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
20-abx135754 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ul
- 50 ul
- 100 ul
- 200 ul
|
|
|
 Antibody) Cancer/Testis Antigen 1 (CTAG1B) Antibody |
|
abx433062-100g |
Abbexa |
100 µg |
EUR 387.5 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
20-abx171540 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx171540-1ml |
Abbexa |
1 ml |
EUR 787.5 |
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
20-abx126874 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx128209-100l |
Abbexa |
100 µl |
EUR 275 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
20-abx128209 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx128209-1ml |
Abbexa |
1 ml |
EUR 750 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx128209-200l |
Abbexa |
200 µl |
EUR 337.5 |
 Antibody (HRP)) Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
abx316206-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
20-abx316206 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
abx316206-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
abx316206-50g |
Abbexa |
50 µg |
EUR 250 |
 Antibody (FITC)) Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
abx316207-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
20-abx316207 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
abx316207-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
abx316207-50g |
Abbexa |
50 µg |
EUR 250 |
 Antibody (Biotin)) Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
abx316208-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
20-abx316208 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
abx316208-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
abx316208-50g |
Abbexa |
50 µg |
EUR 250 |
) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) |
|
MBS6002009-02mL |
MyBiosource |
0.2(mL |
EUR 695 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) |
|
MBS6002009-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
 Polyclonal Antibody) ARMC3 (Cancer/testis antigen 81) Polyclonal Antibody |
|
MBS9238385-01mL |
MyBiosource |
0.1mL |
EUR 415 |
ARMC3 (Cancer/testis antigen 81) Polyclonal Antibody |
|
MBS9238385-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1841 |
 Polyclonal Antibody) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody |
|
CAU21749-100ul |
Biomatik Corporation |
100ul |
EUR 235.2 |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody |
|
CAU21749-200ul |
Biomatik Corporation |
200ul |
EUR 294 |
 (AP)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (AP) |
|
MBS6289627-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (AP) |
|
MBS6289627-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (APC)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (APC) |
|
MBS6289628-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (APC) |
|
MBS6289628-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (FITC)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (FITC) |
|
MBS6289630-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (FITC) |
|
MBS6289630-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (PE)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (PE) |
|
MBS6289637-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (PE) |
|
MBS6289637-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (Biotin)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Biotin) |
|
MBS6289629-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Biotin) |
|
MBS6289629-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (MaxLight 405)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 405) |
|
MBS6289632-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 405) |
|
MBS6289632-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 490)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 490) |
|
MBS6289633-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 490) |
|
MBS6289633-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 550)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 550) |
|
MBS6289634-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 550) |
|
MBS6289634-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 650)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 650) |
|
MBS6289635-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 650) |
|
MBS6289635-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 750)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 750) |
|
MBS6289636-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 750) |
|
MBS6289636-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (Azide free) (HRP)) CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Azide free) (HRP) |
|
MBS6289631-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Azide free) (HRP) |
|
MBS6289631-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
) Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-01mL |
MyBiosource |
0.1mL |
EUR 175 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-02mL |
MyBiosource |
0.2mL |
EUR 220 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-05mL |
MyBiosource |
0.5mL |
EUR 355 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-1mL |
MyBiosource |
1mL |
EUR 435 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-5mL |
MyBiosource |
5mL |
EUR 1185 |
) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) |
|
MBS645319-02mL |
MyBiosource |
0.2mL |
EUR 695 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) |
|
MBS645319-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
 (AP)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (AP) |
|
MBS6289616-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (AP) |
|
MBS6289616-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (APC)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (APC) |
|
MBS6289617-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (APC) |
|
MBS6289617-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (Biotin)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Biotin) |
|
MBS6289618-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Biotin) |
|
MBS6289618-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (FITC)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (FITC) |
|
MBS6289619-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (FITC) |
|
MBS6289619-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 (PE)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (PE) |
|
MBS6289626-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (PE) |
|
MBS6289626-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 Polyclonal Antibody (Human)) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human) |
|
4-PAJ316Hu01 |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B) |
) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) |
|
MBS6007563-01mg |
MyBiosource |
0.1(mg |
EUR 630 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) |
|
MBS6007563-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2680 |
 (PE)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (PE) |
|
MBS6157301-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (PE) |
|
MBS6157301-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (AP)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (AP) |
|
MBS6130786-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (AP) |
|
MBS6130786-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 APC) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) APC |
|
MBS6136089-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) APC |
|
MBS6136089-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (HRP)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (HRP) |
|
MBS6151998-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (HRP) |
|
MBS6151998-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (MaxLight 405)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 405) |
|
MBS6289621-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 405) |
|
MBS6289621-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 490)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 490) |
|
MBS6289622-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 490) |
|
MBS6289622-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 550)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 550) |
|
MBS6289623-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 550) |
|
MBS6289623-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 650)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 650) |
|
MBS6289624-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 650) |
|
MBS6289624-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
 (MaxLight 750)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 750) |
|
MBS6289625-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 750) |
|
MBS6289625-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
) Human Cancer/testis antigen 2 (CTAG2) |
|
1-CSB-EP006127HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 2(CTAG2) expressed in E.coli |
Human Cancer/testis antigen 2 (CTAG2) |
|
1-CSB-YP006127HUa4 |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 2(CTAG2) expressed in Yeast |
) Human Cancer/testis antigen 1 (CTAG1A) |
|
1-CSB-EP006125HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 1(CTAG1A) expressed in E.coli |
 Protein) Cancer/Testis Antigen 5.1 (SSX1) Protein |
|
abx262587-10mg |
Abbexa |
10 mg |
EUR 325 |
Cancer/Testis Antigen 5.1 (SSX1) Protein |
|
abx262587-25mg |
Abbexa |
25 mg |
EUR 6575 |
Cancer/Testis Antigen 5.1 (SSX1) Protein |
|
abx262587-5mg |
Abbexa |
5 mg |
EUR 225 |
Human Cancer/testis antigen 1 (CTAG1A) |
|
1-CSB-YP006125HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 1(CTAG1A) expressed in Yeast |
 (Biotin)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (Biotin) |
|
MBS6141392-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (Biotin) |
|
MBS6141392-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (FITC)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (FITC) |
|
MBS6146695-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (FITC) |
|
MBS6146695-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (Azide free) (HRP)) CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Azide free) (HRP) |
|
MBS6289620-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Azide free) (HRP) |
|
MBS6289620-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
 Polyclonal Antibody (Human), PE) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), PE |
|
4-PAJ316Hu01-PE |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with PE. |
 Polyclonal Antibody (Human), APC) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), APC |
|
4-PAJ316Hu01-APC |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with APC. |
 Polyclonal Antibody (Human), Cy3) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), Cy3 |
|
4-PAJ316Hu01-Cy3 |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with Cy3. |
 Polyclonal Antibody (Human), HRP) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), HRP |
|
4-PAJ316Hu01-HRP |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with HRP. |
 (MaxLight 550)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 550) |
|
MBS6210999-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 550) |
|
MBS6210999-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (MaxLight 405)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 405) |
|
MBS6189649-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 405) |
|
MBS6189649-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (MaxLight 750)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 750) |
|
MBS6232349-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 750) |
|
MBS6232349-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (MaxLight 490)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 490) |
|
MBS6200324-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 490) |
|
MBS6200324-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 (MaxLight 650)) CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 650) |
|
MBS6221674-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 650) |
|
MBS6221674-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
 Polyclonal Antibody (Human), FITC) Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), FITC |
|
4-PAJ316Hu01-FITC |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with FITC. |
 Rabbit anti-human cancer/testis antigen 1A polyclonal Antibody |
|
MBS710901-01mL |
MyBiosource |
0.1mL |
EUR 485 |
Rabbit anti-human cancer/testis antigen 1A polyclonal Antibody |
|
MBS710901-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2175 |
 Recombinant Human Cancer/testis antigen 2 |
|
MBS1166239-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 255 |
Recombinant Human Cancer/testis antigen 2 |
|
MBS1166239-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 405 |
Recombinant Human Cancer/testis antigen 2 |
|
MBS1166239-1mgEColi |
MyBiosource |
1mg(E-Coli) |
EUR 1425 |
These research introduce a paradigm shift with regard to PARP-1 perform in human malignancy, and counsel that the twin capabilities of PARP-1 in DNA injury restore and transcription issue regulation could be leveraged to suppress pathways vital for promalignant phenotypes in prostate most cancers cells by modulation of the DNA injury response and hormone signaling pathways. The mixed research spotlight the significance of twin PARP-1 perform in malignancy and supply the idea for therapeutic focusing on. Lastly, in a novel explant system of major human tumors, focusing on PARP-1 potently suppresses tumor cell proliferation.
